Kaftrio (elexacaftor/tezacaftor/ivacaftor) use was not associated with additional improvements in physical activity among children and adolescents with cystic fibrosis (CF) in a small observational study. Even so, those who started Kaftrio during the study or were already receiving it showed improvements in some health-related quality-of-life domains, including treatment…